Literature DB >> 10871191

Co-expression of HLA DR3 and DQ8 results in the development of spontaneous insulitis and loss of tolerance to GAD65 in transgenic mice.

R S Abraham1, Y C Kudva, S B Wilson, J L Strominger, C S David.   

Abstract

Specific HLA DQ and DR alleles have been associated with susceptibility to type 1 diabetes. HLA DQ8 and DQ2 have been shown to strongly predispose to disease and to be in linkage disequilibrium with at-risk DR4 and DR3 alleles, respectively. Inheritance of a mixed DR3/DR4 haplotype confers the greatest risk. A double transgenic mouse expressing both DR3 and DQ8 was generated to investigate potential major histocompatibility complex class II interactions. The DR3/DQ8 transgenic mice developed a spontaneous loss of tolerance to GAD65, in which the T-cell response to GAD65 was restricted by HLA DR. Although the mice also showed spontaneous insulitis, they did not progress to overt diabetes. Mice expressing either transgene (DQ8 or DR3) alone showed mild infiltration of their islets, which disappeared when DQ8 or DR3 was co-expressed with a resistant DR2 allele or the neutral DQ6 allele. Therefore, in a fashion analogous to human diabetes, the murine model demonstrated a requirement for a combination of at-risk DR and DQ allotypes for the initiation of spontaneous autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871191     DOI: 10.2337/diabetes.49.4.548

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  12 in total

Review 1.  DR, DQ, and you: MHC alleles and autoimmunity.

Authors:  G Sønderstrup; H O McDevitt
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

Review 2.  Molecular aspects of type 1 diabetes.

Authors:  M A Kelly; M L Rayner; C H Mijovic; A H Barnett
Journal:  Mol Pathol       Date:  2003-02

3.  Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity.

Authors:  Anish Suri; James J Walters; Michael L Gross; Emil R Unanue
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

4.  HLA-DRB1 reduces the risk of type 2 diabetes mellitus by increased insulin secretion.

Authors:  R C Williams; Y L Muller; R L Hanson; W C Knowler; C C Mason; L Bian; V Ossowski; K Wiedrich; Y F Chen; S Marcovina; J Hahnke; R G Nelson; L J Baier; C Bogardus
Journal:  Diabetologia       Date:  2011-04-12       Impact factor: 10.122

5.  Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice.

Authors:  Huan Yang; Elzbieta Goluszko; Chella David; David K Okita; Bianca Conti-Fine; Teh-sheng Chan; Mathilde A Poussin; Premkumar Christadoss
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

6.  Autoimmune cardiomyopathy and heart block develop spontaneously in HLA-DQ8 transgenic IAbeta knockout NOD mice.

Authors:  John F Elliott; Junliang Liu; Zuan-Ning Yuan; Norma Bautista-Lopez; Sarah L Wallbank; Kunimasa Suzuki; David Rayner; Patrick Nation; Murray A Robertson; Gang Liu; Katherine M Kavanagh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-21       Impact factor: 11.205

Review 7.  What can the HLA transgenic mouse tell us about autoimmune diabetes?

Authors:  F S Wong; L Wen
Journal:  Diabetologia       Date:  2004-09-02       Impact factor: 10.122

8.  Prevention of type 1 diabetes by gene therapy.

Authors:  Chaorui Tian; Jessamyn Bagley; Nathalie Cretin; Nilufer Seth; Kai W Wucherpfennig; John Iacomini
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

9.  HLA Class II Polymorphisms Modulate Gut Microbiota and Experimental Autoimmune Encephalomyelitis Phenotype.

Authors:  Shailesh K Shahi; Soham Ali; Camille M Jaime; Natalya V Guseva; Ashutosh K Mangalam
Journal:  Immunohorizons       Date:  2021-08-11

10.  Identification of antigenic epitopes on human allergens: studies with HLA transgenic mice.

Authors:  Svetlana P Chapoval; Chella S David
Journal:  Environ Health Perspect       Date:  2003-02       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.